Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development - Test2 - elhamkhani - TriplyDB

Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development

Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development

http://www.wikidata.org/entity/Q27488364

about

Immunogenetic mechanisms driving norovirus GII.4 antigenic variation Development and Characterization of Monoclonal Antibodies to Yellow Fever Virus and Application in Antigen Detection and IgM Capture Enzyme-Linked Immunosorbent Assay A Single Amino Acid Substitution in the M Protein Attenuates Japanese Encephalitis Virus in Mammalian Hosts Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine Plant-produced candidate countermeasures against emerging and reemerging infections and bioterror agents Degrees of maturity: the complex structure and biology of flaviviruses The Complexity of a Dengue Vaccine: A Review of the Human Antibody Response Vaccines in development against West Nile virus Dengue E Protein Domain III-Based DNA Immunisation Induces Strong Antibody Responses to All Four Viral Serotypes A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations A Therapeutic Antibody against West Nile Virus Neutralizes Infection by Blocking Fusion within Endosomes Human Monoclonal Antibodies against West Nile Virus Induced by Natural Infection Neutralize at a Postattachment Step Impact of Quaternary Organization on the Antigenic Structure of the Tick-Borne Encephalitis Virus Envelope Glycoprotein E Tick-borne flaviviruses: dissecting host immune responses and virus countermeasures Complement Protein C1q Reduces the Stoichiometric Threshold for Antibody-Mediated Neutralization of West Nile Virus Dengue virus neutralization is modulated by IgG antibody subclass and Fcγ receptor subtype Natural Strain Variation and Antibody Neutralization of Dengue Serotype 3 Viruses The Development of Therapeutic Antibodies That Neutralize Homologous and Heterologous Genotypes of Dengue Virus Type 1 Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354 Structural Basis of Differential Neutralization of DENV-1 Genotypes by an Antibody that Recognizes a Cryptic Epitope Structure of the St. Louis Encephalitis Virus Postfusion Envelope Trimer Identifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus Species Age affects quantity but not quality of antibody responses after vaccination with an inactivated flavivirus vaccine against tick-borne encephalitis A single mutation in the envelope protein modulates flavivirus antigenicity, stability, and pathogenesis The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis Porcine reproductive and respiratory syndrome (PRRS): an immune dysregulatory pandemic.Defining New Therapeutics Using a More Immunocompetent Mouse Model of Antibody-Enhanced Dengue Virus Infection.Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.Antigenic and Biological Characterization of ORF2-6 Variants at Early Times Following PRRSV Infection Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4 Specificities of human CD4+ T cell responses to an inactivated flavivirus vaccine and infection: correlation with structure and epitope prediction In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection.A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus Influence of pr-M cleavage on the heterogeneity of extracellular dengue virus particles.A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus Development of a humanized antibody with high therapeutic potential against dengue virus type 2 Virus-like particle secretion and genotype-dependent immunogenicity of dengue virus serotype 2 DNA vaccine CD8+ T cells prevent antigen-induced antibody-dependent enhancement of dengue disease in mice Dengue vaccines: recent developments, ongoing challenges and current candidates.

P2860

Q24810360-C8F62C1C-789F-482D-9D96-A54412558324 Q26700079-A85A090C-0E3E-4972-9597-4EA99F9D9FC3 Q26700092-9B8E5FB0-1BAC-4240-8168-24D125E5F24B Q26782367-AC11664A-3539-43B7-B4D0-03E16BECA378 Q26783107-09D18E6B-0452-4DB2-AEBB-6F4396D8CE64 Q26824712-AB5F2BF4-0352-42FC-9359-66C1C189D207 Q26995782-73186E07-F874-411B-A217-F83B5AC93A17 Q26999702-5EDCDC1C-AAC7-4A58-8266-80FED6FA18B3 Q27304342-E3BD848B-94D7-4907-8278-8B5737180A0D Q27321020-408DF142-5EB8-4759-B359-7581D0CE9D7F Q27488367-41C01FB1-DFCC-4629-9625-E7E7C0ADB9AB Q27488791-008F64E7-CA6A-4BCE-BC9B-C46E1B3E10D2 Q27489515-E0038BDB-F95A-4424-9518-29FD73B2E9B7 Q27490363-1EFB6564-0E18-45A6-9424-1728C172F964 Q27490423-EFE98252-77FD-4CB2-A623-839B8439DCE3 Q27490436-6EB21FF1-1C45-4900-8215-E304ADA5E481 Q27491299-9EB439E0-62FB-418F-95FE-D9E57727B737 Q27491317-F2D32E0D-0C09-49D9-AA45-42F2BF95D670 Q27654848-07C9EF9F-7EFB-4E97-BADF-A7FE6EC4A5ED Q27665151-F11ED5C7-F645-4AAB-85BB-4DF1EC83A8B2 Q27674417-91C731E2-9D35-4B5E-8E05-4E279AE37594 Q27674868-0721C465-D969-4EC7-9D64-EBB291AD64F4 Q28119651-4E2FCE42-D318-44F6-B9C7-EAAD41E79303 Q28730933-D706D57B-A5B7-4E80-94E0-4D9F888DB25B Q28804076-9925C6F9-D898-417F-BB5B-65811172DA8C Q28804225-CE596D71-683B-4800-83F3-3BE3AE8155AF Q30364184-962A26E0-7CB6-41E6-8D07-BB4AF28EA11E Q33425879-3C4FA8BA-E904-4CAB-AA48-494102317EE1 Q33610555-0727BCCA-1BA1-43DC-B68D-D88A1974AF0E Q33753971-608719DC-190A-4EEA-902A-F44A81B250C2 Q33852635-68EEC636-3622-407C-86C1-54139AF488CA Q33900413-F3B4EF4E-0E6D-497F-879A-14CD682FAAA1 Q33945441-B695FF32-794B-461D-A7E1-5D0078A29B9F Q33954392-3E815CC6-1E2C-43CC-B937-A48B45CCB93B Q34046013-22D3FE18-B978-45C9-9D5D-98A38566DDFC Q34132718-A131E6C8-A9B9-4293-AD94-AB54D60EC657 Q34260219-B4CA350D-355E-4A8E-9D71-C22C0F0A4ADF Q34262245-2D298723-56A7-4052-9F69-7CA6DCE91B92 Q34289194-4FE640BF-72F9-442D-82B6-B62DB36BD2C3 Q34367194-97838300-3B81-4EE5-A587-0F4750D098AD

P2860

Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development

http://www.wikidata.org/entity/Q27488364

description

2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

article scientifique (publié 2008/09/11)

@fr

articolo scientifico (pubblicato il 2008/09/11)

@it

artigo científico (publicado na 2008/09/11)

@pt

artículu científicu espublizáu en 2008

@ast

im September 2008 veröffentlichter wissenschaftlicher Artikel

@de

scientific article (publication date: 11 September 2008)

@en

vedecký článok (publikovaný 2008/09/11)

@sk

vetenskaplig artikel (publicerad på 2008/09/11)

@sv

name

Structural Insights into the M ...... ations for Vaccine Development

@ast

Structural Insights into the M ...... ations for Vaccine Development

@en

Structural Insights into the M ...... ations for Vaccine Development

@nl

type

label

Structural Insights into the M ...... ations for Vaccine Development

@ast

Structural Insights into the M ...... ations for Vaccine Development

@en

Structural Insights into the M ...... ations for Vaccine Development

@nl

prefLabel

Structural Insights into the M ...... ations for Vaccine Development

@ast

Structural Insights into the M ...... ations for Vaccine Development

@en

Structural Insights into the M ...... ations for Vaccine Development

@nl

P1433

Q27488364-39B84A66-0BBC-452A-BC1E-AF2D903A5BFC

P1476

Q27488364-68BEF51F-6B77-4E42-AF84-382C52AED9BF

P2093

Q27488364-00D59288-700C-4177-8300-8C15744460C8

P2860

Q27488364-01600C13-20C7-4FFD-9FEE-3879586098FE

Q27488364-09B19D9D-7600-4F08-88C2-18AE9D449A35

Q27488364-0A1CE35C-AEFA-47CC-A3BB-344248976806

Q27488364-10B1EBE1-9C85-42E3-89BE-57A33310CA29

Q27488364-11CC2F91-7AFD-432A-AFEB-1F84410F6278

Q27488364-11F73B83-9C61-4B86-A5F8-8680AAEE6491

Q27488364-12767B56-D248-490B-BCD2-44012D8A1CB6

Q27488364-129E07D6-18A8-46D5-9CEE-CDA525808506

Q27488364-13365178-3D54-4490-BD47-8C85E7C74DE6

Q27488364-14F46816-73D2-4A72-8DA0-67FE48F4139E

P304

Q27488364-27844E58-7CF7-4F49-BBCE-F7A88AA2CB84

P31

Q27488364-736FE175-19F2-4C78-B7C8-1DBD6638F2F5

Q27488364-c0d1b7c1-d2de-434f-9b4d-135780b0323e

P3181

Q27488364-A74B0D57-8060-4730-BFBB-95DCC51B9CE1

P356

Q27488364-CD8C5C8B-94E7-4967-A6CB-E63EB129B289

P433

Q27488364-9C418ED9-ED81-4894-B16F-530A038EED24

P478

Q27488364-3B3B0F59-BA46-4448-B7AD-605F35430FED

P50

Q27488364-0022FF3A-AC52-43EF-B9C2-DB851D0D65CE

Q27488364-132FC069-C053-4A28-9F9B-1728D7B4B0B8

Q27488364-E526544B-390C-426B-B2E9-89E3E6F19D8E

P5008

Q27488364-7D321C9B-ECD7-4BB5-8B89-6A56980FCC33

P577

Q27488364-47989DF7-9B70-415B-8260-1C6C3A675CF0

P5875

Q27488364-3B2F8808-0F9A-40C8-A645-8AF1DFEAD721

P698

Q27488364-F2D5E53E-0A57-4F69-B9DC-2DA5D2A0284E

P921

Q27488364-319317A9-04DE-4220-B00B-3C08EC0E64F9

P932

Q27488364-A3BCC79F-C2E9-4B8B-B46F-C4017E268B82

P3181

P356

J.CHOM.2008.08.004

P1433

Cell Host & Microbe

P1476

Structural Insights into the M ...... ations for Vaccine Development

@en

P2093

Daved H Fremont

http://www.w3.org/2001/XMLSchema#string

P2860

Localization and Characterization of Flavivirus Envelope Glycoprotein Cross-Reactive Epitopes

Dengue and dengue hemorrhagic fever

Structure of dengue virus: implications for flavivirus organization, maturation, and fusion

VIPERdb: a relational database for structural virology.

Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.

Complement activation is required for induction of a protective antibody response against West Nile virus infection

Monoclonal Antibodies That Bind to Domain III of Dengue Virus E Glycoprotein Are the Most Efficient Blockers of Virus Adsorption to Vero Cells

Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus

West Nile Virus Discriminates between DC-SIGN and DC-SIGNR for Cellular Attachment and Infection

B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus.

P304

229-38

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1322090

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/J.CHOM.2008.08.004

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Michael S. Diamond

Theodore C Pierson

P5008

P577

2008-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23244824

http://www.w3.org/2001/XMLSchema#string

P698

18779049

http://www.w3.org/2001/XMLSchema#string

P921

P932

2678546

http://www.w3.org/2001/XMLSchema#string